AstraZeneca launches "reshaping for sustainable growth" plan targeting $1.5B annual savings

AstraZeneca is launching a three-year restructuring programme, internally called "reshaping for sustainable growth", expected to deliver $1.5B in annual savings with up to $2B in one-time costs. The company will reinvest the savings into its drug pipeline as it seeks to grow beyond its headline target of $80B revenue by 2030.

Detected & updated continuously · Source: Nebula